Founded in 1989, Genetic Technologies Limited is an established Australian-based molecular diagnostics company specialising in women’s health. The Company offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class.
The Company markets BREVAGenplus to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons).
Released in October 2014, BREVAGenplus® improves upon the predictive power of the first generation BREVAGen™ test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer.
Listed on the ASX (GTG) in 2000 and Nasdaq (GENE) in 2005, Genetic Technologies Limited has established a successful fee-for-service genetic testing business that is primarily focused on the U.S. market. The Company successfully launched the first generation BREVAGen™ test across the U.S. in 2011, via its U.S. subsidiary Phenogen Sciences Inc., and released the second generation BREVAGenplus® test, in October 2014, significantly expanding the applicable market.